Synapse - Find an Expert

50 Results

Stem cell transplantation for multiple myeloma: Current and future status

Journal Article

Giralt, S.
Hematology (2012)

Fulltext@MSK | Save

Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease

Journal Article

Landau, H.; Pandit-Taskar, N.; Hassoun, H.; Cohen, A.; Lesokhin, A.; Lendvai, N.; Drullinsky, P.; Schulman, P.; Jhanwar, S.; Hoover, E.; more...
Leukemia and Lymphoma (2012)

Fulltext@MSK | Save

A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma

Journal Article

Shah, M. A.; Power, D. G.; Kindler, H. L.; Holen, K. D.; Kemeny, M. M.; Ilson, D. H.; Tang, L.; Capanu, M.; Wright, J. J.; Kelsen, D. P.
Investigational New Drugs (2011)

Fulltext@MSK | Save

Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: Cardiac responses and overall effects

Journal Article

Dubrey, S. W.; Reece, D. E.; Sanchorawala, V.; Hegenbart, U.; Merlini, G.; Palladini, G.; Fermand, J. P.; Vescio, R. A.; Blade, J.; Heffner, L. T.; more...
QJM: An International Journal of Medicine (2011)

Fulltext@MSK | Save

Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes

Journal Article

O'Connor, O. A.; Portlock, C.; Moskowitz, C.; Hamlin, P.; Straus, D.; Gerecitano, J.; Gonen, M.; Dumitrescu, O.; Sarasohn, D.; Butos, J.; more...
Clinical Cancer Research (2010)

Fulltext@MSK | Save

Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies

Journal Article

Marchi, E.; Paoluzzi, L.; Scotto, L.; Seshan, V. E.; Zain, J. M.; Zinzani, P. L.; O'Connor, O. A.
Clinical Cancer Research (2010)

Fulltext@MSK | Save

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: Results of a phase 1 dose-escalation study

Journal Article

Reece, D. E.; Sanchorawala, V.; Hegenbart, U.; Merlini, G.; Palladini, G.; Fermand, J. P.; Vescio, R. A.; Liu, X.; Elsayed, Y. A.; Cakana, A.; more...
Blood (2009)

Fulltext@MSK | Save

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: Results of a multicentre phase 2 clinical trial

Journal Article

O'Connor, O. A.; Moskowitz, C.; Portlock, C.; Hamlin, P.; Straus, D.; Dumitrescu, O.; Sarasohn, D.; Gonen, M.; Butos, J.; Neylon, E.; more...
British Journal of Haematology (2009)

Fulltext@MSK | Save

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens